NewLimit

NewLimit

生物技术研究

South San Francisco,California 3,291 位关注者

NewLimit is a biotechnology company working to extend human healthspan by developing epigenetic reprogramming therapies.

关于我们

NewLimit is a biotechnology company working to radically extend human healthspan. We’re developing medicines to treat age-related diseases by reprogramming the epigenome, a new therapeutic mechanism to restore regenerative potential in aged and diseased cells. We leverage functional genomics, pooled perturbation screening, and machine learning models to unravel the biology of epigenetic aging and disease using experiments of unprecedented scale.

网站
https://newlimit.com
所属行业
生物技术研究
规模
11-50 人
总部
South San Francisco,California
类型
私人持股
创立
2022

地点

NewLimit员工

动态

相似主页

查看职位

融资

NewLimit 共 1 轮

上一轮

A 轮

US$40,000,000.00

Crunchbase 上查看更多信息